Gold(III) complexes as a new family of cytotoxic and antitumor agents

References

• Sadler PJ. The biological chemistry of gold: a metallo-drug and heavy-atom label with variable valency. Struct. Bond 29, 171–210 (1976).
   Google Scholar
• Dhubhghaill OM, Sadler PJ. Gold complexes in cancer chemotherapy. In: Metal Complexes in Cancer Chemoterapy. Keppler, B. K (Ed), VCH, Weinheim, 221–248 (1993).
   Google Scholar
• Sadler PJ, Sue RE The Chemistry of gold drugs. Metal Based Drugs 1, 107–144 (1994).
   PubMedGoogle Scholar
• Buckley RG, Elsome AM, Flicker SP et al. Antitumor properties of some 2-[(dimethylamino)methyl] phenylgold(III) complexes.' Med. Chem. 39, 5208–5214 (1996).
   Google Scholar
• Calamai P Carotti S, Guerri A et al. Cytotmdc effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. Anticancer Drug Design 13, 67–80 (1998).
   PubMedGoogle Scholar
• Cossu F, Matovic Z, Radanovic D et al. Cytotmdc activity of some gold(III) complexes. Il Farmaco 49(4), 301–302 (1994).
   PubMedGoogle Scholar
• Mirabelli CK, Johnson RK, Sung CM et al. Evaluation of the in vivo antitumor activity and in vitro cytotmdc properties of auranofin, a co-ordinated gold compound, in muline tumor models. Cancer Res. 45(1), 32–39 (1985).
   Google Scholar
• Crooke ST, Mirabelli CK Molecular mechanisms of action of auranofin and other gold complexes as related to their biological activities. Am. J Med. 75(6A), 109–113 (1983).
   Google Scholar
• Parish RV, Howe BP, Wright JP et al Chemical and biological studies of dichloro(2-((dimethylamino)methyl)phenyl)gold(I11). Inow. Chem. 35, 1659–1666 (1996).
   Google Scholar
• Calamai P, Guerri A, Messori L et al. Structure and DNA binding properties of the gold(III) complex [AuC12(esal)]. Inorg. Chim. Acta 285, 309–312 (1999).
   Google Scholar
• Carotti S, Guerri A, Mazzei T et al. Gold(III) compounds as potential antitumor agents: cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes. Inorg. Chim. Acta 281,90–94 (1998).
   Web of Science ®Google Scholar
• Calamai P, Carotti S, Guerri A et al. Biological properties of two gold(III) complexes: AuC13(Hpm) and AuC12(pm).f Inorg. Biochem. 66, 103–109 (1997).
   Google Scholar
• Messori L, Abbate F, Marcon G et aL Gold(III) complexes as potential antitumor agents: solution chemistry and citotoxic properties of some selected gold(III) compounds." Med Chem. 43(19), 3541–3548 (2000).
   Google Scholar
• Abbate F, Orioli P, Bruni B et al. Crystal Structure and Solution Chemistry of the Cytotoxic Complex 1,2 Dichloro (o-phenanthroline) Gold(III) Chloride Inorg. Chim. Acta 311, 1–5 (2000).
   Google Scholar
• Skehan P Storeng R, Scudiero D et al. New coloiimetric cytotmdcity assay for anticancer-drug screening. J Natl Cancer Inst. 82(13), 1107–1112 (1990).
   Google Scholar
• Macquet JP Butour JL. Platinum-amine compounds: importance of the labile and inert ligands for their pharmacological activities toward L1210 leukemia cells. J Nad Cancer Inst. 70(5), 899–905 (1983).
   Google Scholar
• Mcfayden WD, Wakelin LP, Roos IA et al. Activity of platinum(II) intercalating agents against murine leukemia L1210.i Med. Chem. 28(8), 1113–1116 (1985).
   Google Scholar
• Veal JM, Rill RL. Noncovalent DNA binding of bis (1,10- phenanthroline)copper(I) and related compounds. Biochemistry 30(4), 1132–1140 (1991).
   Google Scholar
• Sigman DS, Landgraf R, Perlin DM et id Nucleic acid chemistry of the cuprous complexes of 1,10-Phenanthroline and derivatives. Met. Ions Biol. Syst. 33, 485–510 (1996).
   Google Scholar
• Tice RR The single cell gel/comet assay: a microgel electrophoretic technique for the detection of DNA damage and repair in individual cells. Phillips DH, Venit S (Eds.), In: Environmental Mutagenesis, 1310S Scientific Publishers, Oxford, UK, 315–339 (1995).
   Google Scholar
• Szinigiero L, Studzian K. H202 as a DNAfragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays. AnaL Biochem. 168(1), 88–93 (1988).
   Google Scholar
• Vaisman A, Varchenko M, Said I et al. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27(1), 54–64 (1997).
   PubMedGoogle Scholar
• Coronnello M, Marcon G, Carotti S et dCytotmdcity, cell cycle effects and DNA binding ability of some gold(111) complexes in human leukemic cells with different cisplatin sensivity. OncoL Res. 12(9/10), 361–370 (2001).
   Google Scholar
• Sekiguchi M, Suzuki, M, Tamada T et al. Effects of cisplatin on cell cycle kinetics, morphological change and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Oncology 53, 19–26 (1996).
   PubMedGoogle Scholar
• Messori L, Marcon G, Tempi C et al. Interactions of selected gold(III) complexes with calf thymus DNA. Biochem. Biophys. Res. Commun. 281(2), 352–360 (2001).
   Google Scholar
• Zamorra F, Zangrando E, Furlan M et al. Au(III) binding to C5 of the model nucleobase 1,3-dimethyluracil (1,3-dimeu)- preparation and x-ray crystal-structures of trans-K[Au(CN)20(1,3- dimeuM and of 2 derivatives. Organomet. Chem. 552(1–2), 127–134 (1998).
   Google Scholar
• Mirabelli CK, Sung CM, Zimmerman JP et al. Interaction of gold co-ordination complexes with DNA. Biochem. Pharmacol. 35(9), 1427–1433 (1986).
   PubMedGoogle Scholar
• Mirabelli CK, Zimmerman JP, Bartus HR et al. Interstrand cross-links and single-strand breaks produced by gold(I) and gold(III) co-ordination complexes. Biochem. Pharmacol. 35(9), 1435–1443 (1986).
   PubMedGoogle Scholar